Drugs News and Research

RSS

Albireo to present study results of A3309 in patients with chronic constipation at 2010 DDW annual meeting

Albireo today announced that additional clinical data will be reported from a recent study assessing the safety, tolerability and efficacy of A3309 in patients with chronic constipation. A3309 is a first-in-class investigational compound for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic constipation (CC). The results will be presented during the 2010 Digestive Disease Week (DDW) annual meeting being held in New Orleans, US.

29 Apr 2010

Injection drug use contributes to transmission of syphilis

A binational team of researchers led by University of California, San Diego School of Medicine have discovered that active syphilis infections are significantly greater in female sex workers who inject drugs and share needles than those who don't. The findings suggest that injection drug use may play as big a role as risky sexual behavior in the transmission of syphilis. It may also exacerbate the spread of both HIV and syphilis, as syphilis is frequently a co-factor for HIV infection.

29 Apr 2010

CINJ trial targets new combination therapy for advanced solid tumors

Building off recent laboratory discoveries relating to how cancer cells become resistant to therapies that attempt to starve cancer, scientists at The Cancer Institute of New Jersey (CINJ) are now applying that knowledge to a process in which cancer cells eat themselves to downsize and resist therapy. The ultimate goal of this effort is to improve upon current anticancer treatments.

29 Apr 2010

Mass. legislation to push poor seniors into managed care plans stirs concerns

Legislation that could push more than 100,000 low-income senior citizens in Massachusetts into managed care health plans spurred intense lobbying yesterday, as consumer advocates argued the measure would strip patients of their freedom to stay in traditional Medicare, while proponents said it could save the state significant money.

29 Apr 2010

Astrazeneca settles drug marketing lawsuit, plea deal rejected for possibly defective heart device maker

The New York Times: AstraZeneca has settled a case and agreed to pay $520 million after federal investigations into its marketing practices for a schizophrenia drug, Seroquel. The announcement came Tuesday from Attorney General Eric Holder. Government officials, including Health and Human Services Secretary Kathleen Sebelius, said the company paid illegal kickbacks to doctors to promote drugs for unapproved uses by children, the elderly, veterans and prisoners, which is illegal under federal law.

29 Apr 2010

Pain Therapeutics reports net loss of $1.0 million for first-quarter 2010

Pain Therapeutics, Inc., a biopharmaceutical company, today reported first quarter 2010 financial results. Net loss for Q1 2010 was $1.0 million, or $0.02 per share, compared to a net loss of $1.8 million, or $0.04 per share, for Q1 2009.

29 Apr 2010

Higher the blood cholesterol level, greater the risk of atherosclerosis: Study

In addition to crystallized cholesterol, atherosclerotic plaques always contain large quantities of immune cells but, surprisingly, no bacteria or viruses. It was previously unclear just how the body's own defence forces are called into action. Even animals that are kept in an absolutely sterile environment can suffer from "clogging" or "furring" of the arteries when their food contains high levels of cholesterol.

29 Apr 2010

Geron reports net loss of $16.6M for first-quarter 2010

Geron Corporation today reported financial results for the three months ended March 31, 2010.

29 Apr 2010

Fluorescent inhibitors hold promise for early-stage tumor detection

A series of novel imaging agents could light up tumors as they begin to form - before they turn deadly - and signal their transition to aggressive cancers.

29 Apr 2010

Adamas Pharmaceuticals presents study results of TCAD therapy in immunocompromised influenza A patients

Adamas Pharmaceuticals, Inc., a privately held company, announced today the results from the first clinical study evaluating triple combination antiviral drug (TCAD) therapy for the treatment of influenza A in immunocompromised patients. Data from this Phase 1b study were presented by clinical investigator Dr. Janet Englund in a clinical symposium at the 23rd International Conference on Antiviral Research (ICAR) in San Francisco.

29 Apr 2010

Study calls for optimized medical treatment for older patients with advanced lung cancer

Although more than two fifths of lung cancers are diagnosed in patients over 70, data from clinical trials on the safest and most effective treatments for this age group are scarce.

29 Apr 2010

Overhaul may cost drugmakers more than expected

Bloomberg BusinessWeek: The health overhaul legislation will likely cost drugmakers $25 billion more than the $80 billion the industry anticipated when it agreed to back the Democratic-led effort, according to Wall Street analysts. "The extra costs will come from expanding drug rebates through Medicaid, the U.S. insurance program for the poor, [Leerink Swann & Co executive] John L. Sullivan said today at a Bloomberg conference in Chicago."

29 Apr 2010

A new approach for treating neurological and degenerative disorders

In studies on cancer, heart disease, neurological disorders and other degenerative conditions, some scientists are moving away from the "nature versus nurture" debate, and are finding you're not a creature of either genetics or environment, but both - with enormous implications for a new approach to health.

29 Apr 2010

Lycera to advance discovery, development efforts with second tranche of $11 million Series A financing

Lycera Corporation, a biopharmaceutical company pioneering an innovative approach to developing novel oral medicines to treat autoimmune diseases, today announced that the company has made important progress, triggering a second tranche of $11 million in its Series A financing. Proceeds from the second tranche will be used to continue to advance Lycera's discovery and development efforts and further support the growth of the company.

29 Apr 2010

Phase 1B/2 clinical study to evaluate efficacy of PMX-60056 in reversing heparin levels initiated

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has initiated a Phase 1B/2 dose-ranging clinical study with its anticoagulant reversing agent, PMX-60056. The study is intended to demonstrate the safety and efficacy of PMX-60056 in reversing varying heparin levels, including the highest levels commonly used in surgical settings.

29 Apr 2010

Imaging costs for Medicare cancer patients on the rise

A study in the Journal of the American Medical Association analyzed data from Medicare cancer patients to determine the change in imaging use for this group.

29 Apr 2010

Stalk structure of Mx protein restrains components of influenza virus in infected cells

When the human body becomes infected with new influenza viruses, the immune system rapidly activates an inborn protective mechanism to inhibit the intruding pathogen. A protein known as Mx plays an important role in this process, keeping the spread of viruses in check. Exactly how Mx accomplishes this task was previously unknown.

28 Apr 2010

Distinct gender differences underlying risks for abuse of prescription pain drugs: Study

There are distinct gender differences underlying the risks for abuse of prescription pain drugs, according to a Harvard study published in The Journal of Pain, the peer review journal of the American Pain Society, www.ampainsoc.org and www.jpain.org.

28 Apr 2010

Researchers find Alzheimer's pathology to originate from Amyloid-Beta oligomers in the brain

Using a new mouse model of Alzheimer's disease, researchers at Mount Sinai School of Medicine have found that Alzheimer's pathology originates in Amyloid-Beta (Abeta) oligomers in the brain, rather than the amyloid plaques previously thought by many researchers to cause the disease.

28 Apr 2010

AHF applauds Merck for doubling Isentress discount rebates and freezing price for ADAPs

Following an innovative, years long advocacy campaign spearheaded by AIDS Healthcare Foundation (AHF) that targeted Merck and Co. Pharmaceuticals over the pricing of its AIDS drug Isentress—one of the most expensive first line AIDS therapies on the US market today—officials from AHF lauded Merck today for significant concessions that the drug giant is putting in place on its pricing and rebate policies for the nation's AIDS Drug Assistance Programs (ADAP), the federally funded, state run programs that supply lifesaving AIDS drugs to low-income Americans in need.

28 Apr 2010

Drugs News and Research

Albireo to present study results of A3309 in patients with chronic constipation at 2010 DDW annual meeting

Injection drug use contributes to transmission of syphilis

CINJ trial targets new combination therapy for advanced solid tumors

Mass. legislation to push poor seniors into managed care plans stirs concerns

Astrazeneca settles drug marketing lawsuit, plea deal rejected for possibly defective heart device maker

Pain Therapeutics reports net loss of $1.0 million for first-quarter 2010

Higher the blood cholesterol level, greater the risk of atherosclerosis: Study

Geron reports net loss of $16.6M for first-quarter 2010

Fluorescent inhibitors hold promise for early-stage tumor detection

Adamas Pharmaceuticals presents study results of TCAD therapy in immunocompromised influenza A patients

Study calls for optimized medical treatment for older patients with advanced lung cancer

Overhaul may cost drugmakers more than expected

A new approach for treating neurological and degenerative disorders

Lycera to advance discovery, development efforts with second tranche of $11 million Series A financing

Phase 1B/2 clinical study to evaluate efficacy of PMX-60056 in reversing heparin levels initiated

Imaging costs for Medicare cancer patients on the rise

Stalk structure of Mx protein restrains components of influenza virus in infected cells

Distinct gender differences underlying risks for abuse of prescription pain drugs: Study

Researchers find Alzheimer's pathology to originate from Amyloid-Beta oligomers in the brain

AHF applauds Merck for doubling Isentress discount rebates and freezing price for ADAPs

Drug Discovery - Second Edition eBook

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News